a-galcer

α-Galactosylceramide (KRN7000) 是一种具有抗肿瘤和免疫刺激作用的合成糖脂。它是一种高效的 NKT 细胞激动剂，可与 CD1d 有效结合。它与 CD1d 的复合物可与 NKT 细胞的 T 细胞抗原受体结合。

KRN7000 analog 3（Compound 14），这种α-GalCer类似物具有4-苯氧基替代基，是一种高效的iNKT激动剂。在mNK1.2细胞中，KRN7000 analog 3诱导的IL-2细胞因子分泌水平（49.2-62.6 ng mL）显著高于α-GalCer（44.1 ng mL）。因此，KRN7000 analog 3在抗肿瘤药物和疫苗佐剂的开发中具有潜在的应用价值。

α-Galactosylceramide analog 8 (α-GalCer analog 8) is a triazole derivative of α-galactosylceramide. [1] It increases IL-2 secretion by DN32.D3 NKT hybridoma cells when co-cultured with CD1d-transfected RBL cells pre-loaded with α-GalCer analog 8 at a concentration of 32 ng ml. α-GalCer analog 8 (32 ng ml) induces IL-4 secretion to a greater extent than the synthetic α-GalCer KRN 7000 in mouse splenocytes in vitro and in mouse serum following administration of a 1 µg per animal dose, indicating a Th2 response.

KBC-007 is a synthetic branched chain-containing analog of α-galactosylceramide (α-GalCer). It induces IL-4 and IFN-γ secretion by mouse splenocytes when used at a concentration of 0.5 ng/ml and IL-2 secretion by DN32.D3 NKT hybridoma cells co-cultured with CD1d-transfected RBL cells pre-loaded with KBC-007 at a concentration of 8 ng/ml. KBC-007 (1 μg per animal) increases levels of IL-4, but not IFN-γ, to a similar degree as α-GalCer in mouse serum. KBC-007 (0.5 μg per animal) increases the survival rate of mice immunized with the inactivated influenza A virus A/PR/8/34 in a model of influenza infection.